中间期PSMA PET在前列腺癌化疗中是否有作用
本文综述了细胞毒性药物对PSMA表达的影响以及PSMA PET用于疗效评估的现有数据。传统影像基于RECIST 1.1评估前列腺癌疗效受限,骨扫描因闪烁现象延迟进展检测,可靠的化疗疗效影像工具仍被需要。PSMA PET能否实现这一目标仍存争议。
要点
- RECIST 1.1在前列腺癌疗效评估中作用有限,因病灶常仅表现为硬化性骨改变。
- 骨扫描因闪烁现象导致进展检测显著延迟,基于分子影像的疗效评估已被提出并用于临床试验。
- PSMA PET能否可靠评估前列腺癌化疗疗效仍存争议,本综述汇总细胞毒性药物对PSMA表达影响及PSMA PET疗效评估数据。
核心结论
- 前列腺癌化疗疗效评估仍缺乏稳健可靠的影像工具,PSMA PET能否胜任仍存争议。
研究设计与样本
- 综述,汇总细胞毒性药物对PSMA表达影响及PSMA PET用于疗效评估的现有数据。
主要发现
- RECIST 1.1在前列腺癌中应用受限,因疾病在常规影像上常仅见硬化性骨改变。
- 基于分子影像(包括骨扫描)的疗效评估已被提出并用于临床试验,但骨扫描闪烁现象导致进展检测显著延迟。
局限性
- 原文指出前列腺癌化疗仍缺乏稳健可靠的影像疗效评估工具,PSMA PET能否实现该目标仍存争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While RECIST 1.1 is well established in radiological response assessment, it is of limited use in prostate cancer (PCa) considering that the disease is often seen only as sclerotic bone changes on conventional imaging. Therefore, a molecular imaging-based response assessment including bone scans has been proposed and used in clinical trials, however, due to the flare phenomenon on bone scans this assessment leads to substantial delays in the detection of progression. Indeed, a robust and reliable imaging tool to assess response to chemotherapy in PCa is still warranted. Whether Positron Emission Tomography (PET) targeting the Prostate-Specific Membrane Antigen (PSMA) could achieve this, is still controversial. In this review, we summarized the available data on cytotoxic agents and their impact on PSMA expression, as well as the available data on PSMA PET imaging for response assessment.
引用
- Laudicella R, Bauckneht M, Burger IA, et al. Is There a Role of Interim PSMA PET in Chemotherapy of Prostate Cancer? Semin Nucl Med. 2023. PMID: 37599149. doi:10.1053/j.semnuclmed.2023.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。